Recombinant
RabMAb

Recombinant Anti-Cytochrome P450 17A1/CYP17A1 antibody [EPR6293] (HRP) (ab204022)

Overview

  • Product name

    Anti-Cytochrome P450 17A1/CYP17A1 antibody [EPR6293] (HRP)
    See all Cytochrome P450 17A1/CYP17A1 primary antibodies
  • Description

    Rabbit monoclonal [EPR6293] to Cytochrome P450 17A1/CYP17A1 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide within Cytochrome P450 17A1/CYP17A1. The exact sequence is proprietary.

  • Positive control

    • WB: HeLa and Jurkat whole cell lysates.
  • General notes

     This product was previously labelled as Cytochrome P450 17A1

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Applications

Our Abpromise guarantee covers the use of ab204022 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 57 kDa (predicted molecular weight: 57 kDa).

Target

  • Function

    Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
  • Pathway

    Lipid metabolism; steroid biosynthesis.
  • Involvement in disease

    Defects in CYP17A1 are the cause of adrenal hyperplasia type 5 (AH5) [MIM:202110]. AH5 is a form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: "salt wasting" (SW, the most severe type), "simple virilizing" (SV, less severely affected patients), with normal aldosterone biosynthesis, "non-classic form" or late onset (NC or LOAH), and "cryptic" (asymptomatic).
  • Sequence similarities

    Belongs to the cytochrome P450 family.
  • Post-translational
    modifications

    Phosphorylation is necessary for 17,20-lyase, but not for 17-alpha-hydroxylase activity.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • 20 lyase antibody
    • CP17A_HUMAN antibody
    • CPT7 antibody
    • CYP17 antibody
    • CYP17A1 antibody
    • CYPXVII antibody
    • Cytochrome P450 17A1 antibody
    • Cytochrome P450 family 17 antibody
    • Cytochrome P450 family 17 subfamily A polypeptide 1 antibody
    • Cytochrome p450 subfamily XVII (steroid 17 alpha hydroxylase) adrenal hyperplasia antibody
    • Cytochrome p450 XVIIA1 antibody
    • Cytochrome P450-C17 antibody
    • Cytochrome P450c17 antibody
    • OTTHUMP00000020382 antibody
    • P450 C17 antibody
    • P450c17 antibody
    • S17AH antibody
    • Steroid 17 alpha hydroxylase/17,20 lyase antibody
    • Steroid 17 alpha monooxygenase antibody
    • Steroid 17-alpha-hydroxylase/17 antibody
    • Steroid 17-alpha-monooxygenase antibody
    see all

Images

  • All lanes : Anti-Cytochrome P450 17A1/CYP17A1 antibody [EPR6293] (HRP) (ab204022) at 1/5000 dilution

    Lane 1 : HeLa whole cell lysate (ab150035)
    Lane 2 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 57 kDa
    Observed band size: 57 kDa


    Exposure time: 3 minutes


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab204022 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab204022 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab204022.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up